Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06324435 · ClinicalTrials.gov registry record · Phase 1
Apremilast for Alcohol Use Disorder Treatment in Women and Men
A Phase 1 study of Alcohol Use Disorder, sponsored by Yale University.
- Active
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06324435: Active Phase 1 study of Alcohol Use Disorder, sponsored by Yale University.
NCT06324435 is a Phase 1 study of Alcohol Use Disorder that is active but no longer recruiting, run by Yale University. The registered enrollment target is 10 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06324435, a Phase 1 study of Alcohol Use Disorder, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
For this protocol, the investigators plan to collect pilot data to evaluate apremilast (60mg/day) in adults with Alcohol Use Disorders (AUD).
Primary Outcome
Means mls of alcohol consumed during 120 minute alcohol self-administration sessions with personalized stress imagery vs neutral/relaxing imagery taking place at steady state.
Conditions Studied
Interventions
- DRUG Apremilast
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-05-08 |
| Est. Completion | 2026-08-30 |
| Phase | Phase 1 |
What the registry record for NCT06324435 still lists
NCT06324435 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Apremilast is the first listed.
NCT06324435 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06324435 about?
NCT06324435 is a clinical study titled "Apremilast for Alcohol Use Disorder Treatment in Women and Men". For this protocol, the investigators plan to collect pilot data to evaluate apremilast (60mg/day) in adults with Alcohol Use Disorders (AUD).
What is the current status of trial NCT06324435?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-05-08. Estimated completion is 2026-08-30.
What conditions does trial NCT06324435 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT06324435?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT06324435?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06324435 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06324435's enrollment target sits among peer trials
10 181st of 184 higher than 3 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin for Treatment of Alcohol Use Disorder
RECRUITING · Phase 1
-
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
RECRUITING · Phase 1
-
Environment and Alcohol: A Pilot Study
RECRUITING · Phase 1
-
PET Imaging of Phosphodiesterase-4B (PDE4B) in Alcohol Use Disorder
RECRUITING · Phase 1
-
Sex Differences in the Response to Abstinence From Alcohol.
RECRUITING · Phase 1
-
PT150 Drug for Use in Alcohol Use Disorder
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI